← Back to Screener
MiniMed Group, Inc. Common Stock (MMED)
Price$12.00
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (4W)-5.55%
VGM Score60.83
Market Capitalization$3.38B
All Metrics
P/CF (Annual)82.47x
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-47.39%
10-Day Avg Trading Volume0.64M
EPS (Annual)$-0.40
ROI (Annual)-3.28%
Gross Margin (Annual)58.20%
ROA (Last FY)-2.76%
Cash Flow / Share (Annual)$-0.38
Net Income / Employee (Annual)$-14,100
EPS Incl Extra (Annual)$-0.40
Current Ratio (Annual)1.73x
3-Month Avg Trading Volume1.00M
P/S Ratio (Annual)1.37x
Asset Turnover (Annual)0.60x
52-Week High$20.48
EPS Excl Extra (Annual)$-0.40
Quick Ratio (Annual)1.16x
Total Debt / Equity (Annual)0.00x
Revenue / Employee (Annual)$308,600
Pretax Margin (Annual)-2.84%
Cash / Share (Annual)$0.19
ROE (Last FY)-3.28%
EPS Basic Excl Extra (Annual)$-0.40
Revenue / Share (Annual)$8.79
Year-to-Date Return-34.88%
5-Day Price Return1.43%
EPS Normalized (Annual)$-0.40
Net Profit Margin (Annual)-4.58%
Month-to-Date Return-2.43%
EBITD / Share (Annual)$-0.21
Operating Margin (Annual)-2.79%
Beta1.36x
52-Week Low$10.65
mGradeB
vgmGradeB
Show chart for
Analyst Recommendations
Apr 2026
May 2026
4.15
4.21
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MMEDMiniMed Group, Inc. Common Stock | — | — | B | $12.00 |
| SYKStryker Corporation | C | C | D | $299.46 |
| MMM3M Company | C | F | C | $150.93 |
| BSXBoston Scientific Corp. | C | B | F | $47.98 |
| MDLNMedline Inc. Class A common stock | C | D | D | $35.75 |
| BDXBecton, Dickinson and Co. | B | C | C | $145.33 |
| DXCMDexCom, Inc. | C | B | C | $74.87 |
| RMDResMed Inc. | B | B | D | $186.44 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $316.30 |
| SOLVSolventum Corporation | C | D | C | $75.84 |
| PENPenumbra, Inc. | F | C | C | $318.95 |
About
MiniMed Group develops and manufactures diabetes management solutions, including automated insulin pumps, continuous glucose monitoring systems, and smart insulin pens. The company generates revenue from sales of reusable and single-use products—both automated insulin delivery and smart multiple daily injection systems—distributed globally through direct-to-consumer and healthcare provider channels.